Abstract 1243P
Background
Ocular surface squamous neoplasia (OSSN) is a common eye surface neoplastic disease ranging from non-invasive conjunctival intraepithelial neoplasia (CIN) to invasive forms of squamous cell carcinoma (SCC) that accounts for approximately 10% of ocular surface lesions. Early detection of OSSN is crucial for effective treatment. However, clinical symptoms of OSSN vary, which can result in delayed or inappropriate diagnosis without appropriate diagnostic methods. Currently, the diagnosis of OSSN relies on clinical suspicion confirmed by impression cytology or biopsy, which are invasive and may not detect small lesions. This study aims to introduce an artificial intelligence data analysis framework to empower a newly designed autofluorescence hyperspectral imaging technology developed in our group for OSSN detection.
Methods
We recruited 20 patients who had previously been diagnosed with OSSN. Biopsy specimens were collected from the patients and reprocessed without staining to obtain autofluorescence microscopy images using 25 spectral channels, each with a distinctive excitation-emission wavelength. The spectral images were pre-processed to remove unwanted random noise and then spectral features were extracted from the epithelial section of tissue images. Further, the spectral features were used to form an artificial feature image patch to train a convolutional neural network for image classification.
Results
The technique was evaluated against pathological assessment, and results showed the multispectral analysis was able to detect OSSN in all tested patients (P-value < 0.05). The trained classifier on OSSN and normal sections was found to have great performance (AUC > 83%). The maps produced by the analysis were in close agreement with margins observed in H&E sections. The fully automated diagnostic method based on AI methodology produced maps of the neoplastic-non neoplastic interface that could be generated in quasi-real time and used for intraoperative assessment.
Conclusions
The study demonstrated the feasibility of using AI empowered hyperspectral autofluorescence imaging to detect OSSN and the potential for the technique to be used as a diagnostic tool in future clinical applications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Institute NSW.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1807P - Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status
Presenter: Nobuaki Matsubara
Session: Poster session 14
1808P - Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m<sup>2</sup>) versus every 3 weeks (25 mg/m<sup>2</sup>) in the CABASTY phase III trial
Presenter: Stephane Oudard
Session: Poster session 14
1809P - Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
Presenter: Nicole Brighi
Session: Poster session 14
1810P - Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
Presenter: Michael Morris
Session: Poster session 14
1811P - Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study
Presenter: Andre Fay
Session: Poster session 14
1813P - Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
Presenter: Andrew Laccetti
Session: Poster session 14
1814P - First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France
Presenter: Anne-Laure Giraudet
Session: Poster session 14
1815P - Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1
Presenter: Elena Castro
Session: Poster session 14